<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274284</url>
  </required_header>
  <id_info>
    <org_study_id>Bl Cancer</org_study_id>
    <nct_id>NCT03274284</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy for Recurrent T1G3 Bladder Cancer</brief_title>
  <official_title>Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the short term results of chemoradiation in case of T1G3 BC after BCG failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non- muscle invasive bladder cancer (NMIBC) is a heterogeneous group of cancers. For most
      urologists the treatment of T1G3 tumor poses a dilemma of management.The spectrum of clinical
      behavior includes; T1 lesions that will not progress however T1G3 may be potentially lethal,
      associated with metastatic disease at the time of presentation.

      The major goal of treatment for T1G3 BC should be bladder preservation whenever possible.

      Intravesical therapy with Bacille Calmette Guerin (BCG) may decrease the recurrence rate by
      compared with transurethral resection of bladder tumor (TURBT) alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Result of chemoradiation for recurrentT1G3 BC after BCG failure</measure>
    <time_frame>followup within two years</time_frame>
    <description>treatment of 20 patients with recurrent T1G3
BC by chemoradiation to see efficacy and safety .and to reduce the number of recurrent cases and improve survival.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>chemoradiation</intervention_name>
    <description>chemoradiation in case of T1G3 BC after BCG failure.</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with recurrent T1G3 bladder cancer after 6 doses of BCG consenting for
             chemoradiation and refusing radical cystectomy

        Exclusion Criteria:

          -  Any patients with distant metastasis or positive LN on CT or MRI.

          -  Patients unfit for chemoradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Moeen</last_name>
    <role>Study Director</role>
    <affiliation>Moeen3@yahoo.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>moktar dawood</last_name>
    <phone>+201009442860</phone>
    <email>mokhtardawood@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diaa El Din Mohamed</last_name>
    <phone>+201001229936</phone>
    <email>Diaa-hameed@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007 Jul;100(1):33-6.</citation>
    <PMID>17552951</PMID>
  </reference>
  <reference>
    <citation>Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002 Apr;167(4):1573-83.</citation>
    <PMID>11912367</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MokhtarDawood</investigator_full_name>
    <investigator_title>Assistant Lecturer of Urology</investigator_title>
  </responsible_party>
  <keyword>chemoradiation for</keyword>
  <keyword>T1G3 BC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

